Last edition
News about "Quadruple-class"
Bristol Myers Squibb’s arlo-cel demonstrated statistically significant and clinically meaningful responses in patients with quadruple-class exposed relapsed and refractory multiple myeloma.
Quadruple-class | 09/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members